Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 9 of 9

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

PULSAR Extension: Clinical improvements maintained over 156 weeks with aflibercept 8 mg in patients with neovascular age-related macular degeneration

Timothy Y Y Lai; David T Wong; Tien Y Wong; Paolo Lanzetta; Jean-Francois Korobelnik; Frank G Holz; Taiji Sakamoto; Sobha Sivaprased; Andrea Schulze; Ursula Schmidt-Ott; Xin Zhang; Alyson Berliner; Karen W Chu; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):438.

ARVO Annual Meeting Abstract June 2024

Comparable efficacy with aflibercept 8 mg at extended dosing intervals beyond q16 versus 2 mg q8 in Asian patients with nAMD in PULSAR through Week 96

Xiaodong Sun; Shih-Jen Chen; xin Zhang; Andrea Schulze; Tobias Machewitz; Min Zhao; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):220.

ARVO Annual Meeting Abstract June 2024

Aflibercept 8 mg monotherapy shows maintained efficacy over 96 weeks, with the ability to extend dosing intervals beyond every 16 weeks, in patients with PCV in the PULSAR Phase 3 trial

Rufino Silva; Tien Y Wong; Gemmy Cheung; Jeffrey S Heier; Won Ki Lee; Tomohiro Iida; xin Zhang; Tobias Machewitz; Andrea Schulze; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):219.

ARVO Annual Meeting Abstract June 2024

Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg

Andreas Stahl; Eric Schneider; Ursula Maria Schmidt-Ott; Claudia Tueckmantel; Andrea Schulze; Alyson J Berliner; Karen W Chu; Robert Vitti; Kimberly Reed; xin Zhang; Peter Morgan-Warren; Rohini Rao; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):217.

ARVO Annual Meeting Abstract June 2023

Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration

Jean-Francois Korobelnik; Ursula Maria Schmidt-Ott; Andrea Schulze; Xin Zhang; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):278.

ARVO Annual Meeting Abstract June 2023

Intravitreal aflibercept 8 mg in patients with polypoidal choroidal vasculopathy (PCV): A Phase 3 PULSAR trial subgroup analysis

Tien Y Wong; Jeffrey S Heier; Xin Zhang; Tobias Machewitz; Andrea Schulze; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2240.

ARVO Annual Meeting Abstract June 2021

The Role of Extended Phenotyping and Functional Testing in Variant Interpretation of a Complex Patient with Overlapping Traits

Zhuo Shao; Ikuo Masuho; Anupreet Tumber; Jason Maynes; Erika Tavares; Stacy Hewson; Andreas Schulze; Peter Kannu; Kirill A Martemyanov; Ajoy Vincent

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1562.

Glaucoma November 2012

Structure-Function Relationship between FDF, FDT, SAP, and Scanning Laser Ophthalmoscopy in Glaucoma Patients

PDF

Julia Lamparter; Richard A. Russell; Andreas Schulze; Ann-Christin Schuff; Norbert Pfeiffer; Esther M. Hoffmann
TAGS: glaucoma, scanning laser ophthalmoscopy, perimetry
Invest. Ophthalmol. Vis. Sci.. 2012; 53(12):7553-7559. https://doi.org/10.1167/iovs.12-10892

Includes: Supplemental Content

ARVO Annual Meeting Abstract March 2012

Influence Of Pupil Dilation On Fourier-domain Optical Coherence Tomography (FD-OCT) Measurements In Glaucoma And Normal Subjects

Andreas Schulze; Julia Lamparter; Norbert Pfeiffer; Esther M. Hoffmann

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):680.

Advertisement